● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available (oral since 2018, IV since 2022).
TPOXX tecovirimat Updated Oct 28
What to watch
The next hard catalyst is Q3 2026 earnings on November 5, 2026, which will show whether TPOXX deliveries continued and whether management has secured a new multi-year BARDA procurement contract. Without a new contract, the revenue cliff from the nearly-exhausted 19C contract is the dominant risk. The longer-term catalyst is the planned FDA submission for post-exposure prophylaxis in H1 2027, but that is over six months away and not yet a binary event.
Bull case
- TPOXX is the only FDA-approved drug specifically indicated for smallpox, a critical biodefense asset stockpiled by the U.S. Strategic National Stockpile and over 30 countries (source: siga.com).
- SIGA is targeting an FDA submission for post-exposure prophylaxis (PEP) in H1 2027, which could expand TPOXX's addressable market beyond treatment of active disease (source: seekingalpha.com).
- The company has a strong patent portfolio with 26 U.S. utility patents and 101 issued foreign patents protecting TPOXX (source: stocklight.com).
Bear case
- ~86% of the $630M BARDA 19C contract has already been exercised, leaving a thin revenue backlog and a looming revenue cliff (source: panabee.com).
- Q2 2026 revenue fell 49% YoY to $41M and EPS dropped to $0.17 from $0.49; Q1 2026 revenue was just $6.2M, showing extreme quarter-to-quarter volatility (source: tradingkey.com).
- Two major mpox trials (PALM 007 and STOMP) failed to meet primary endpoints, and the EMA recommended withdrawing the mpox indication for tecovirimat in March 2026, removing a key growth thesis (source: bioworld.com).